drugset / Trial / NCT00660192

Investigation of Efficacy and Safety of Botulinum Toxin A (Botox-Allergan Inc) in Migraine Headaches

NCT00660192

Phase 2/3 Completed 25 enrolled Yale University
RandomizedParallel-groupDouble-blindTreatment

Summary

The hypothesis of this study is that injection of botulinum toxin A into the muscles around the head (frontal, temporal, posterior neck, occipital) can reduce the intensity and frequency of migraine headaches by 50%.

Timeline

Start
2008-01
Primary completion
2012-07
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum toxin type A Protein / enzyme biologic 200 iu Intramuscular
Comparator Botulinum toxin type A Protein / enzyme biologic 300 iu Intramuscular

Indications